<DOC>
	<DOCNO>NCT00388167</DOCNO>
	<brief_summary>We want determine efficacy safety caspofungin acetate ( CANCIDAS® ) treatment invader fungal infection ( IFI ) specifically , Invasive Candidiasis ( CI ) adults patient without neutropenia Invasive Aspergillosis ( AI ) adults patient refractory intolerant therapy ( i.e. , amphotericin B , lipid formulation amphotericin B , and/or itraconazole ) .</brief_summary>
	<brief_title>Acetato de Caspofungin ( Cancidas® ) Treatment Fungal Infection</brief_title>
	<detailed_description>Study post-marketing ( observational ) . It multicenter prospective . No masking use , without control group neither randomize</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Caspofungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>Female male 18 year old least . Diagnosis AI CI . It base Clinical History , sign symptoms patient take , discovery study radiology result cultivation and/or study anatomopathology positive Candida spp . Aspergillus spp . Patients AI , must refractory intolerant therapy antifungal use hospital . Patients CI , must refractory intolerant therapy antifungal use hospital . Patients diagnosis uncertain base one next criterion : Cultivation positive Candida localization ( urine , spittle , end/current catheter ; osteomyelitis endocarditis Candida without treatment appropriated surgical ; infection Candida prosthetic material without retire ; positive blood cultive Candida appearance vascular prosthesis ; allergic lung Aspergillosis ; aspergilloma aspergillosis eye without treatment appropriated surgical ) . Allergic / hypersensitivity caspofungin . Insufficiency several liver ( rate ChilePugh &gt; 9 ) . Prediction survival &lt; 5 day . Pregnant breast feeding . Previous Participation patient study . Presence disease condition mix interpretation result create risk . Previous Participation patient clinical study involve administration drug investigation 14 day previous inclusion study administration caspofungin . We include patient take antineoplastic drug research whenever left Investigator Coordinator authorize</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Invader fungal infection ( IFI )</keyword>
	<keyword>Invasive Aspergillosis ( AI )</keyword>
	<keyword>Invasive Candidiasis ( CI )</keyword>
	<keyword>Caspofungin acetate</keyword>
</DOC>